MAPK14: Mitogen-activated protein kinase 14
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway.
- Drugs that act on it: 35
- Approved: 0
- In phases 1 to 3: 35
- Sponsors: 16
Who is on it, and how far along
Every drug ChEMBL records acting on MAPK14, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 25
- Other 10
Approved0
Phase 32
Phase 218
Phase 115
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- GSK39%
- Pfizer39%
- Array Biopharma, now a wholly owned subsidiary of Pfizer13%
- AstraZeneca Pharmaceuticals13%
- Boehringer Ingelheim Pharmaceuticals13%
- Bristol-Myers Squibb13%
- EIP Pharma Inc13%
- Eli Lilly13%
- Ferring Pharmaceuticals13%
- Johnson & Johnson13%
| ARRY-797 | Phase 3 | Pfizer | Small molecule | Inhibitor | 0 |
| Losmapimod | Phase 3 | GSK | Small molecule | Inhibitor | 0 |
| Neflamapimod | Phase 2 | EIP Pharma Inc | Small molecule | Inhibitor | 1 |
| Pexmetinib | Phase 2 | Array Biopharma, now a wholly owned subsidiary of Pfizer | Small molecule | Inhibitor | 1 |
| Acumapimod | Phase 2 | Mereo BioPharma | Small molecule | Inhibitor | 0 |
| AZD-7624 | Phase 2 | AstraZeneca Pharmaceuticals | Small molecule | Inhibitor | 0 |
| BMS-582949 | Phase 2 | Bristol-Myers Squibb | Small molecule | Inhibitor | 0 |
| Dilmapimod | Phase 2 | GSK | Small molecule | Inhibitor | 0 |
| Doramapimod | Phase 2 | Boehringer Ingelheim Pharmaceuticals | Small molecule | Inhibitor | 0 |
| FX-005 | Phase 2 | Pacira Pharmaceuticals | Other | Inhibitor | 0 |
| ITX-5061 free base | Phase 2 | Kemia, Inc | Small molecule | Inhibitor | 0 |
| Pamapimod | Phase 2 | — | Small molecule | Inhibitor | 0 |
| PF-03715455 | Phase 2 | Pfizer | Small molecule | Inhibitor | 0 |
| PG-760564 | Phase 2 | Procter & Gamble | Other | Inhibitor | 0 |
| PH-797804 | Phase 2 | Pfizer | Small molecule | Inhibitor | 0 |
| Ralimetinib | Phase 2 | Eli Lilly | Small molecule | Inhibitor | 0 |
| Semapimod | Phase 2 | Ferring Pharmaceuticals | Small molecule | Inhibitor | 0 |
| TAK-715 | Phase 2 | Takeda Pharmaceuticals USA | Small molecule | Inhibitor | 0 |
| Talmapimod | Phase 2 | Johnson & Johnson | Small molecule | Inhibitor | 0 |
| VX-702 | Phase 2 | Vertex Pharmaceuticals | Small molecule | Inhibitor | 0 |
| AMG-548 | Phase 1 | — | Small molecule | Inhibitor | 0 |
| AVE-9940 | Phase 1 | — | Other | Inhibitor | 0 |
| AZD-6703 | Phase 1 | — | Small molecule | Inhibitor | 0 |
| GSK-610677 | Phase 1 | GSK | Other | Inhibitor | 0 |
| LEO-15520 | Phase 1 | — | Other | Inhibitor | 0 |
| LY-3007113 | Phase 1 | — | Other | Inhibitor | 0 |
| PS-516895 | Phase 1 | — | Other | Inhibitor | 0 |
| R-1487 | Phase 1 | — | Small molecule | Inhibitor | 0 |
| RO-3201195 | Phase 1 | — | Small molecule | Inhibitor | 0 |
| RWJ-67657 | Phase 1 | — | Small molecule | Inhibitor | 0 |
| SB-85635 | Phase 1 | — | Other | Inhibitor | 0 |
| SC-80036 | Phase 1 | — | Other | Inhibitor | 0 |
| SCIO-323 | Phase 1 | — | Small molecule | Inhibitor | 0 |
| SD-0006 | Phase 1 | — | Small molecule | Inhibitor | 0 |
| TA-5493 | Phase 1 | — | Other | Inhibitor | 0 |
| Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia | Neflamapimod | Phase 2 | Active, not recruiting | EIP Pharma Inc | Jun 24, 2025 |
| Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | Pexmetinib | Phase 1 / Phase 2 | Active, not recruiting | Dan Zandberg | Aug 30, 2019 |
- Neurodegenerative disease0.46
- Autoimmune disorder of central nervous system0.46
- Alzheimer disease0.34
- Parkinson disease0.32
- Lysosomal storage disease0.30
- Facioscapulohumeral muscular dystrophy0.30
- COVID-190.29
- Acute coronary syndrome0.26
- Ulcerative colitis0.22
- Melanoma0.21
- Spondyloarthropathy0.21
- Ankylosing spondylitis0.21
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL260, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-19. Gene name, function (UniProt Q16539, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets